\n<\/p>\n
Chai Discovery, a biotech startup with backing from OpenAI, announced<\/a> an $130 million Series B round at a $1.3 billion valuation on Monday. <\/p>\n The round was led by General Catalyst and Oak HC\/FT, the company said. Other participants include Menlo Ventures, OpenAI, Dimension, Thrive Capital, Neo, Yosemite venture fund, Lachy Groom, SV Angel, and new investors Glade Brook and Emerson Collective. The firm\u2019s total funding now stands at over $225 million.<\/p>\n The company is one in a growing industry<\/a> that sees AI as a faster route towards drug development. In August, Menlo Ventures announced it<\/a> was leading Chai\u2019s $70 million Series A round. The investor described Chai as a startup that was building foundation models tuned for drug discovery, specifically to predict interactions between biochemical molecules so they could be reprogramed for cures.<\/p>\n Chai says that its ambition is to \u201cbuild the \u201ccomputer aided design suite\u201d for molecules.\u201d Last year, the startup announced the<\/a> Chai 1 AI model and is now offering Chai 2, it\u2019s latest model. The company says Chai 2 is achieving significant improvements in success rates over other methods for de novo antibody design, meaning building custom antibodies from scratch, not modifying existing ones.<\/p>\n \u201cOur latest models can design molecules that have properties we\u2019d want from actual drugs, and tackle challenging targets that have been out of reach,\u201d Josh Meier, Chai\u2019s co-founder and CEO said in a prepared statement. <\/p>\n Previously, Meier, who\u2019s background is in machine learning, worked in research and engineering at Facebook and, prior to that, worked for OpenAI, according to his LinkedIn<\/a>. Chai Discovery was founded in 2024, the profile notes.<\/p>\n